New hope for SMA: yearly injection aims to boost muscle function
NCT ID NCT07444476
Summary
This study is testing a new drug called salanersen (BIIB115) for people aged 15-60 with spinal muscular atrophy (SMA). The goal is to see if it can improve muscle movement and function. It will include people who have never had SMA treatment and those who are switching from the drug risdiplam. Participants will receive the drug as a yearly injection into the spinal fluid for up to five years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPINAL MUSCULAR ATROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.